Chu de Bordeaux - Hăpital Haut-Lăvăque

Pessac 33604

0 studies enrolling now · 8 studies all time

What they study most

Acute Myeloid Leukemia, Borderline Resectable Pancreatic Cancer, Diffuse Large B-Cell Lymphoma, Diffuse Large B-cell Lymphoma, Leukemia, Liver Cirrhosis, Biliary, Lymphoma, SBRT, Small Cell Lung Cancer and Breast Cancer, Unresectable Pancreatic Cancer

Studies at this site

• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML — Running, not enrolling
• Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma — Stopped early
• A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) — Running, not enrolling
• Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas — Stopped early
• Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) — Stopped early
• Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer — Stopped early
• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis — Stopped early
• Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) — Stopped early